{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T03:05:40Z","timestamp":1768273540599,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.7759\/cureus.97871","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:26:47Z","timestamp":1764181607000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacist-Led Prevention of Recurrent Cetuximab Infusion Reactions"],"prefix":"10.7759","author":[{"given":"Yota","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arisa","family":"Fukuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyasu","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Fukue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Akasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Imakyure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"FDA. Erbitux (cetuximab) [prescribing information]. (2025). Accessed. September 17, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125084s273lbl.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyu049","article-title":"Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan","volume":"44","author":"Yamaguchi K","year":"2014","unstructured":"Yamaguchi K, Watanabe T, Satoh T, et al.. Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan. Jpn J Clin Oncol. 2014, 44:541-6. 10.1093\/jjco\/hyu049","journal-title":"Jpn J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung CH","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, et al.. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008, 358:1109-17. 10.1056\/NEJMoa074943","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.7812","article-title":"High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history","volume":"25","author":"O'Neil BH","year":"2007","unstructured":"O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol. 2007, 25:3644-8. 10.1200\/JCO.2007.11.7812","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe GA","year":"2018","unstructured":"Isabwe GA, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018, 142:159-170.e2. 10.1016\/j.jaci.2018.02.018","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.12.1947","article-title":"The alpha-gal story: lessons learned from connecting the dots","volume":"135","author":"Steinke JW","year":"2015","unstructured":"Steinke JW, Platts-Mills TA, Commins SP. The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015, 135:589-96. 10.1016\/j.jaci.2014.12.1947","journal-title":"J Allergy Clin Immunol"},{"key":"ref7","unstructured":"European Medicines Agency. Erbitux (cetuximab). summary of product characteristics. (2023). Accessed: September 17, 2025: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230424159203\/anx_159203_en.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102922","article-title":"Management of infusion-related reactions in cancer therapy: strategies and\u00a0challenges","volume":"9","author":"Barroso A","year":"2024","unstructured":"Barroso A, Estevinho F, Hespanhol V, Teixeira E, Ramalho-Carvalho J, Ara\u00fajo A. Management of infusion-related reactions in cancer therapy: strategies and\u00a0challenges. ESMO Open. 2024, 9:102922. 10.1016\/j.esmoop.2024.102922","journal-title":"ESMO Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/all.15032","article-title":"EAACI guidelines: anaphylaxis (2021 update)","volume":"77","author":"Muraro A","year":"2022","unstructured":"Muraro A, Worm M, Alviani C, et al.. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022, 77:357-77. 10.1111\/all.15032","journal-title":"Allergy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10192-4","article-title":"Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?","volume":"22","author":"Dupont M","year":"2022","unstructured":"Dupont M, Carlier C, Gower-Rousseau C, et al.. Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?. BMC Cancer. 2022, 22:1219. 10.1186\/s12885-022-10192-4","journal-title":"BMC Cancer"},{"key":"ref11","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Erbitux\u00ae (cetuximab) injection 100, 200. Japanese package insert. (2024). Accessed: September 17, 2025: https:\/\/www.pmda.go.jp\/."},{"key":"ref12","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0. (2017). Accessed. September 17, 2025: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development#ctcae-and-ctep-codes."},{"key":"ref13","unstructured":"Role & Responsibility Charting (RACI). Web v3.1. (2005). Accessed. September 17, 2025: https:\/\/pmicie.org\/files\/22\/PM-Toolkit\/85\/racirweb31.pdf."},{"key":"ref14","unstructured":"Queensland Health. Clinical governance framework for rapid response to COVID-19 outbreaks in residential aged care facilities. Version 1.0. (2020). Accessed. September 17, 2025: https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0018\/1016262\/Clinical-Governance-Framework-RACF-COVID.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.09.015","article-title":"Anaphylaxis: a 2023 practice parameter update","volume":"132","author":"Golden DB","year":"2024","unstructured":"Golden DB, Wang J, Waserman S, et al.. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024, 132:124-76. 10.1016\/j.anai.2023.09.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2000.109445","article-title":"Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists","volume":"36","author":"Lin RY","year":"2000","unstructured":"Lin RY, Curry A, Pesola GR, et al.. Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann Emerg Med. 2000, 36:462-8. 10.1067\/mem.2000.109445","journal-title":"Ann Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231212640","article-title":"Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions","volume":"30","author":"Lofy M","year":"2024","unstructured":"Lofy M, Jung L, Dow-Hillgartner E. Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions. J Oncol Pharm Pract. 2024, 30:412-6. 10.1177\/10781552231212640","journal-title":"J Oncol Pharm Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14062","article-title":"Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment","volume":"40","author":"Rombouts MD","year":"2020","unstructured":"Rombouts MD, Swart EL, van den Eertwegh AJ, Crul M. Systematic review on infusion reactions to and infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res. 2020, 40:1201-18. 10.21873\/anticanres.14062","journal-title":"Anticancer Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.08.028","article-title":"Drug allergy: a\u00a02022 practice parameter update","volume":"150","author":"Khan DA","year":"2022","unstructured":"Khan DA, Banerji A, Blumenthal KG, et al.. Drug allergy: a\u00a02022 practice parameter update. J Allergy Clin Immunol. 2022, 150:1333-93. 10.1016\/j.jaci.2022.08.028","journal-title":"J Allergy Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100553","article-title":"Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection","volume":"14","author":"Park KH","year":"2021","unstructured":"Park KH, Lee J, Beom SH, et al.. Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection. World Allergy Organ J. 2021, 14:100553. 10.1016\/j.waojou.2021.100553","journal-title":"World Allergy Organ J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/422277-pharmacist-led-prevention-of-recurrent-cetuximab-infusion-reactions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:26:49Z","timestamp":1764181609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/422277-pharmacist-led-prevention-of-recurrent-cetuximab-infusion-reactions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.97871","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}